NCT04920539View on ClinicalTrials.gov

In Vivo Study of THC-induced Immune-genome Changes at Single Cell Solution in HIV-infected Humans

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 8, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
HIV InfectionsHealthy
Interventions
DRUG

Active Delta-9-THC

Active Delta-9-THC (0.03 mg/kg) administered intravenously.

Trial Locations (1)

06516

RECRUITING

VA Connecticut Healthcare System, West Haven

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Yale University

OTHER